Takeda announces oncology and cardiovascular deals

4 August 2017
2019_biotech_test_vial_discovery_big

Japan's largest pharma company, Takeda Pharmaceutical (TSE: 4502), has announced two deals with USA-based biotech firms in as many days.

On Thursday, the company announced the creation of a new development partnership with Cardurion, a recently-launched biotech focused on the development of next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases.

Takeda will jumpstart the new company’s discovery efforts by providing a 12-person cardiovascular research team from a site in Shonan, Japan, including development resources and licenses to a portfolio of preclinical-stage cardiovascular drug programs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology